Sunshine Biopharma Inc. — Form 8-K
Filed July 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Sunshine Biopharma and subsidiary Nora Pharma settled all disputes with Malek Chamoun (former President and CEO of Nora, who sold his shares to Sunshine in October 2022 and was terminated April 10, 2025) via a mutual release agreement executed July 8, 2026. Settlement totals $1.5M CAD, allocated as: $479,208 earn-out under original share purchase agreement (paid by Sunshine); $752,782 and $219,561 bonuses for 2024 and Jan–Apr 2025 (paid by Nora); $25,634 severance in lieu of notice; and $22,815 expense reimbursement. Chamoun must sell all Sunshine shares within 30 days; payment due within 10 days of sale evidence. Both parties release all claims; Chamoun's non-compete obligations are terminated, but confidentiality obligations remain.
Why this rating
Settlement of $1.5M CAD equals ~21% of company's $7.1M market cap—material cash outlay for small biotech. Founder/former CEO dispute resolution removes litigation uncertainty but signals prior governance/transaction tensions.
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.